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Abstract
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The factors contributing to osteonecrosis of the jaw (ONJ) with anti-remodeling drug treatment are
unclear. Both epidemiological and experimental studies have suggested the combination of
bisphosphonates and dexamethasone results in ONJ more often than either agent alone. The goal
of this study was to assess the combination of these two drugs in a large animal model previously
shown to be susceptible to exposed bone in the oral cavity when treated with bisphosphonates.
Skeletally mature beagle dogs were either untreated controls, or treated with zoledronic acid
(ZOL), dexamethasone (DEX), or ZOL + DEX. Both zoledronic acid and dexamethasone were
given at doses based on those used in humans. All animals underwent single molar extraction at
both 7 and 8 months following the start of the study. Extraction sites were obtained at month 9 for
assessment of osseous healing using micro-computed tomography and histology. No animals were
observed to have exposed bone following dental extraction yet one animal treated with ZOL and
one with ZOL+DEX had severely disrupted extraction sites as viewed by CT and histology. These
two animals had intense periosteal reaction that was less obvious but still present on all ZOLtreated animals and absent from untreated animals. There was no significant difference in bone
volume within the socket among groups at either 4 or 8 weeks post-healing yet the surface/volume
ratio was significantly higher in animals treated with ZOL+DEX at 8 weeks compared to control
animals. These findings suggest a more complex pathophysiology to ONJ than is implied by
previous epidemiological studies as well as those in rodents and raise questions about the potential
role of dexamethasone in its etiology.
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INTRODUCTION
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For nearly a decade the condition known as osteonecrosis of the jaw (ONJ) has been as a
rare but significant issue in the field of oral and maxillofacial surgery. First thought to be
specific to bisphosphonates, it is now recognized to be generalizable to potent remodeling
suppression drugs including denosumab [1]. The majority of ONJ cases have manifested in
cancer patients [2–4] with a smaller number of cases reported in patients treated for other
skeletal conditions such as osteoporosis [4, 5]. Despite a low incidence rate [4, 6], ONJ
remains a significant concern due to its unknown pathophysiology and the millions of
patients who are currently taking anti-remodeling agents.
Two risk factors common to epidemiological studies are dental extraction and
dexamethasone treatment. Although ONJ has been documented to occur spontaneously, it is
most commonly associated with trauma induced by a dental procedure. When the incidence
of ONJ is separately assessed for various populations treated with BPs (osteoporosis, Paget’s
disease, and cancer treatment patients), there is a consistent 10-fold increase in ONJ when
dental extraction was concomitant with BP treatment. Corticosteroid treatment has also been
repeatedly suggested as a potential contributor to ONJ.
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The notion of dental extraction and dexamethasone as risk factors for ONJ has been
supported by pre-clinical research. Using various animal models, dental extraction has been
shown to increase the incidence of exposed bone [7]. Combining dental extraction and
dexamethasone in these models exacerbates the number of animals that develop exposed
bone. Since the first report of an ONJ animal model in 2008 which developed a model using
both bisphosphonate and dexamethasone [8], the majority of studies have continued to use
the combination of these drugs, along with dental extraction, to study the condition. One
potential limitation of the studies to date is that they all utilize rodents, animals that lack
significant intracortical remodeling under normal conditions [9]. To increase the
translatability of work in rodents it is important to confirm the findings in a model that more
closely mimics human bone physiology by undergoing intracortical remodeling.
The goal of this study was to document how the combination of bisphosphonates and
dexamethasone affect the mandibular bone tissue following dental extraction in a large
animal model previously shown to be susceptible to ONJ. Specifically, we tested the
hypothesis that zoledronic acid and dexamethasone would significantly increase the number
of animals that develop ONJ, and significantly compromise extraction site healing,
compared to either treatment alone.

NIH-PA Author Manuscript

MATERIALS AND METHODS
Animals
Twenty-four skeletally mature female beagles (~ 1–2 years old) were purchased from
Marshall Farms USA (North Rose, NY) and housed throughout the experiment in
environmentally controlled rooms at Indiana University School of Medicine’s AAALAC
accredited facility. All animal procedures were approved prior to the study by the IU School
of Medicine Animal Care and Use Committee.
Experimental Design
Following two weeks of acclimatization, animals were assigned to untreated control (CON;
n=6), zoledronic acid (ZOL; n=6), dexamethasone (DEX; n=6) or zoledronic acid plus
dexamethasone (ZOL+DEX; n=6) treatment groups. ZOL was administered via intravenous
infusion at a dose of 0.06 mg/kg, which corresponds to the 4 mg dose used in cancer
J Oral Maxillofac Surg. Author manuscript; available in PMC 2014 June 01.
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patients, adjusted on a mg/kg basis [10], and work done previously in our lab [11]. ZOL was
infused every 2 weeks, roughly twice as frequently as used clinically in order to maximize
drug exposure during the experimental period. IV administration (40 mL total volume over
15 minutes) was done using an over-the-needle catheter in the leg vein (rotated for each
infusion between the cephalic and saphenous). Dexamethasone treatment consisted of daily
oral dosing (5 mg) for the first seven days of the 7th, 8th, and 9th months of the experiment.
This dosing was based on a modified version of a low- dose protocol used clinically for
multiple myeloma patients [12].
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Eight months after the first ZOL dose, all animals underwent dental extraction of the 4th
right premolar; one month later (start of the 9th month) all animals underwent extraction of
the 4th left premolar. This design allows two different post-extraction times (four and eight
weeks) to be studied in the same animals and matches those periods previously shown to
detect treatment-related differences. Forth premolars were extracted as previously described
[11]. Briefly, following pre-surgical antibiotics, animals were anesthetized, given an intraoral regional block of the inferior alveolar nerve, and intubated with continuous isofluorane
for the duration of the surgery. The epithelial attachment of the tooth was severed, the crown
split down the middle and each of the two roots was removed individually by gripping
forceps to the crown and then rocking back and forth in the buccal-lingual direction. In the
case where the root was fractured during extraction the root was left intact and the socket
was ignored for all analyses (Table 1). Following extraction the gingival tissue was closed
using absorbable suture. Post-operative analgesia was given for 24 hours post-surgery.
All animals were administered calcein (5 mg/kg, intravenous) using a 2-12-2-5 schedule
(labels were injected on two consecutive days, twelve days were allowed to pass, another
two consecutive days of label were given, and then the animals were euthanized five days
later) to allow dynamic histomorphometry analyses. At the start of the 10th month relative to
the first ZOL dose, animals were euthanized by intravenous administration of sodium
pentobarbital and the right and left mandibles, right 9th rib, and right tibia were dissected
free and placed in 70% ethanol for analysis.
In vivo extraction site healing (oral lesion visualization)
All animals were assessed daily post-extraction for exposed bone in the oral cavity. Our
criterion for classification of ONJ was if exposed bone existed at the extraction site within 4
weeks post-extraction. This time-period is two-times longer than the reported duration of
normal epithelial closure in untreated beagles [13]. Our previous work has shown exposed
bone and sequestration during this time frame in beagle dogs [11].
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Micro-computed tomography of extraction site
The extraction sites of both the left and right hemimandibles were prepared and scanned as
in previous studies [11]. Bone regions were isolated by making parallel buccal-lingual cuts
with a diamond wire saw (Histosaw; Delaware Diamond Knives). Each entire extraction site
was scanned using high-resolution micro-computed topography at a resolution of 8 microns
(Skyscan 1172, Belgium) as previously described [11]. For each extraction site both sockets
were assessed and the data averaged to get a single value for each site with the exception of
cases where one root was fractured, for those animals only the socket with a successful
complete extraction was analyzed. Volume and morphology of the bone within the socket
was assessed in three dimensions by using a region of interest to isolate the socket from the
surrounding bone followed by thresholding of this region to separate mineralized tissue from
the marrow. Outcome parameters of the extraction socket bone consisted of bone volume/
tissue volume (BV/TV, %) and bone surface/total volume (BS/TV, 1/mm).

J Oral Maxillofac Surg. Author manuscript; available in PMC 2014 June 01.
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Histological Processing
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The extraction sites of both the left and right hemimandibles were processed for histological
analyses following microCT analyses. A portion of the rib (located at the greatest curvature),
and a portion of the tibia (~4 cm proximal to the distal end) were also prepared and analyzed
to assess the treatment effects on non-oral high (rib) and low (tibia) remodeling sites.
All tissue segments were stained with basic fuchsin in order to assess bone matrix necrosis
[14]. Using 1% basic fuchsin dissolved in increasing concentrations of ethanol (80%, 95%,
and 100%), specimens were stained for 48 hours per step. Following basic fuchsin staining,
bones were embedded in plastic and then sectioned (~100 µm thick) using a diamond wire
saw (Histosaw; Delaware Diamond Knives). Two sections, separated by ~400 µm, were cut
for each bone region; mandible sections were made as parallel buccal-lingual cuts near the
center of one root socket.
Histological Assessment
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Histological measurements were made using a semiautomatic analysis system (Bioquant
OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a microscope (Nikon Optiphot 2
microscope, Nikon) with a fluorescent light source. For assessment of intra-cortical bone
formation rate, one cross-section was assessed at each skeletal site in accordance with our
previous work [11, 14]. For mandible sections, data were collected separately for alveolar
bone regions (defined as bone above the most distally observed portion of the tooth root or
extraction socket) and non-alveolar bone regions (below the tooth root). The cortical bone of
the entire cross section of the rib and tibia was assessed. All measures and calculations are
similar to those reported previously [11] and are in accordance with ASBMR recommended
standards [15]. Bone matrix necrosis of the cortical bone was assessed by bright-field
microscopy as previously described [14]. Regions of bone void of basic fuchsin stain >500
µm2 were considered necrotic.
Statistics
Statistical tests were performed using SAS software (SAS Institute, Inc.). Parameters were
compared between groups using one-way ANOVA with pLSD post-hoc tests. Differences in
extraction site properties were compared between time-points (4- and 8- weeks postextraction) within each treatment group using paired t-tests. For all tests, p < 0.05 was
considered to be statistically significant.

RESULTS
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Absence of exposed bone and matrix necrosis
All extraction sites healed without noticeable visual incident and no exposed bone or
sequestra were observed. There was also no evidence of matrix necrosis, as defined by
histological analyses of basic fuchsin stained tissue, in any mandible sections.
MicroCT imaging reveals severe bone destruction in select zoledronate animals
Although visual observation suggested normal healing in all animals, CT scanning ex vivo
revealed two animals with severely compromised socket healing. One animal treated with
ZOL and one treated with ZOL+DEX had extraction socket morphology that clearly differed
from all other animals both within their own treatment groups, as well as the other two
treatment groups (Figure 1). These sockets had minimal new tissue formation within the
socket and clear destruction of the pre-existing alveolar bone tissue. There was also
periosteal reaction (new bone formation) noted in both these animals. Histological sections
confirmed CT morphologies in which both animals had destruction of alveolar bone and
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abundant periosteal reaction (Figure 2). The two animals with compromised healing were
excluded from all subsequent analyses.
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Zoledronate alters distribution of bone within healing socket and this is further altered by
addition of dexamethasone
There was no significant difference in extraction socket bone volume (BV/TV) or
morphology (BS/TV) among groups after 4 weeks of healing (Figure 3). By week 8 postextraction, there was significantly higher bone volume compared to 4 weeks in all groups
and this was not affected by treatment. At the eight-week time point ZOL and ZOL+DEX
animals had significantly higher BS/TV compared to CON animals (+8 and +20%,
respectively). BS/TV declined significantly between 4 and 8 weeks for all groups except
ZOL+DEX. Qualitative assessment of CT images revealed modest periosteal reaction on the
majority of ZOL and ZOL+DEX animals while such assessment was notably absent from
CON and DEX only groups (Table 1).
Zoledronate suppression of intracortical remodeling is not altered with the addition of
dexamethasone
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At 4-weeks post-extraction, alveolar bone intracortical remodeling was significantly lower
in ZOL and ZOL+DEX groups compared to CON (Figure 4A and B). There was no effect of
DEX compared to CON or of ZOL+DEX compared to ZOL. Similar patterns among the
groups were observed at 8-weeks post extraction. Animals treated with ZOL, either with or
without DEX, had significantly lower labeled osteon number and bone formation rate
compared to CON and DEX.
At the rib, a site with high bone remodeling rates comparable to alveolar bone, DEX
produced a significantly lower number of labeled osteons relative to CON, although bone
formation rate was not significantly different between groups (Table 2). Labeled osteon
number was significantly lower in ZOL and ZOL+DEX compared to both CON and DEX.
At the tibia, a site with low turnover, DEX, ZOL, and ZOL+DEX produced equivalent
reductions in labeled osteon number compared to CON (Table 2).

DISCUSSION
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Bisphosphonates, dexamethasone, and dental extraction have each been identified as risk
factors for ONJ in retrospective clinical studies and the combination of these three factors
has produced a phenotype similar to ONJ in several rodent experiments. The results of the
current study show that prolonged high dose zoledronic acid and short- term dexamethasone
are not sufficient to produce exposed bone in the oral cavity even following dental
extraction in a beagle dog.
We, and others, have previously documented that zoledronic acid produced rapid and
profound reductions in bone remodeling of the dog mandible [11, 16, 17]. Furthermore, it
has been shown that dental extraction produces regions of non-viable bone matrix, exposed
bone, and sequestra formation in dogs treated for just one month at the same doses of
zoledronate used in the current study [11]. It was therefore unexpected that in the current
study, when zoledronate was given for 7–8 months prior to dental extraction, no animals
deveioped exposed bone. Our findings question the concept that duration of anti-remodeling
treatment is linked to the risk of developing exposed bone following dental extraction.
Although epidemiological studies suggest treatment duration is a risk factor for ONJ, there
are a number of reports of cases in patients treated for just a weeks/months who develop
exposed bone [6, 18].
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Although no animals presented with exposed bone post-extraction, one animal treated with
zoledronate and one treated with zoledronate plus dexamethasone had significantly
compromised bone healing based on CT assessments at 8 weeks post-extraction. These two
animals had alveolar sockets that were notably absent of bone compared to other animals in
their treatment groups (Figure 1). They also had striking loss of alveolar bone, with clear
resorption pits, as well as profound amounts of periosteal woven bone on the buccal surface.
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The observation of periosteal reaction is of interest given the recent report documenting
periosteal reaction in a rat model of periodontal-induced ONJ as well as in patients with
ONJ [24]. These studies showed 6 of 19 animals treated with zoledronate and induced to
have periodontal disease had evidence of periosteal reaction. Although the two animals with
abnormal osseous healing in the current work had profound periosteal reaction, reexamination of all animals in our study qualitatively revealed the presence of smaller
amounts of periosteal reaction in a majority of animals treated with zoledronate. There was
no sign of any periosteal reaction in non-zoledronate treated animals. Furthermore,
retrospective examination of images from ONJ patient sequestra that our lab has scanned
with high-resolution CT revealed a number of samples that contain tissue morphologically
consistent with woven bone on a periosteal surface (Figure 5). The mechanism and
implications of these findings are unclear. It has been suggested that extensive periosteal
reactionary formation, such as can occur with osteitis, is mechanically mediated. In the two
extreme cases where dramatic bone resorption was observed in the current study, the
mechanical forces on the area were likely altered and the periosteal bone could have been an
attempt to compensate. In the other zoledronate treated animals, the mechanical environment
is likely was also altered because of the lack of cortical consolidation following dental
extraction. Irrespective of the underlying reason, the emerging identification of periosteal
reaction associated with ONJ in both animal models and humans suggests it may be an invivo biomarker for identification of abnormally healing sites that have potential for
becoming ONJ. More work to understand the relationship, if any, between periosteal
reaction and ONJ seems warranted.
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Our results regarding extraction site healing and alveolar remodeling activity are consistent
with our previous studies and indicate that neither duration of zoledronate treatment (3
versus 9 months), nor adding dexamethasone to zoledronic acid dramatically alters these
processes. Dexamethasone, zoledronate, or the combination did not affect the initial filling
of the bone socket with bone, as evident by the similar bone volumes among groups at both
4 and 8 weeks. This is consistent with the idea that bisphosphonates to not alter osteoblast
activity in vivo, yet contradicts the idea that dexamethasone induces osteoblast apoptosis,
although the later findings are mostly based on high-dose chronic dosing. The effects of
low-dose dexamethasone on osteoblasts have not been explored in detail. The combination
of zoledronate and dexamethasone did compromise the remodeling of socket healing, as
shown by the lack of reduction in bone surface/total volume, a measure of how the bone is
distributed in the socket. The lack of significant decrease from 4 to 8 weeks suggest the bone
that fills the socket is not being resorbed and replaced by cortical bone, as occurs in
untreated animals [11]. Such findings are expected given the prominent inhibitory effect of
zoledronate on resorption. The reason by zoledronate alone did not produce this effect is
unclear, as it has been shown to previously [11].
The lack of exposed bone in the current work is in stark contrast to a number of studies in
which the combination of zoledronate and dexamethasone produce exposed bone in rodents.
The reason for this discrepancy is unclear, although several differences in models exist
including drug dosing (rodent studies tend to use higher doses), post-extraction protocols
(sites are sutured in dogs, but tend not to be in rodents), and dexamethasone protocol (the
current study used low-dose intermittent treatment consistent with that used for multiple
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myeloma patients). Irrespective of the reason for differences among model systems there are
several potentially important implications. Although there is an association between
dexamethasone and ONJ in human studies the results from rodent studies should not be
considered definitive evidence of a direct role of dexamethasone in the etiology of ONJ.
Secondly, these conflicting results across models demonstrate the importance of pursing
several model systems to study the pathophysiology of ONJ.
In conclusion, we document that prolonged treatment with high-dose zoledronate and
dexamethasone does not produce exposed bone following dental extraction in a beagle dog
model. These findings point to a more complex ONJ pathophysiology than is implied by
previous studies in rodents and raise questions about the role of dexamethasone in its
etiology. Furthermore our experiment shows a small cohort of zoledronate-treated animals
without exposed bone yet with dramatic alterations in post- extraction healing which is
accompanied by extensive periosteal reaction.
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Figure 1.

Micro-computed tomography assessment of the extraction site in a zoledronate-treated
animal (A) and each of the two zoledronate-treated animals that had abnormal healing (B
and C). Images represent the mid-socket cross-section at 8 weeks post-extraction. Clear
morphological differences can be observed between those that have abnormal healing
compared to the zoledronate-treated animals including lack of alveolar socket woven bone,
highly irregular/scalloped surfaces, and intense periosteal bone formation on the buccal
surface.
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Figure 2.

Histological appearance of non-healing socket in zoledronate-treated animal. Consistent
with the CT images, the histological section revealed dramatic destruction of the alveolar
bone (A) and dramatic periosteal bone formation (A,B,C). The periosteal bone was
continuing to form even 8 weeks post-extraction as evident by the osteoblasts and osteoid
(C).
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Figure 3.
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Micro-computed tomography assessment of the extraction site osseous healing. Threedimensional analysis of the entire socket region support document that after 4 weeks of
healing there was no difference in bone volume/tissue volume (BV/TV, %) or bone surface/
total volume among the groups. After 8 weeks of healing, BV/TV was significantly higher
in all treatment groups compared to the 4 week time-point. Bone surface / total volume (BS/
TV) was significantly lower at 8 weeks compared to 4 weeks in CON, DEX, and ZOL
groups but not ZOL+DEX. At the 8-week time point BS/TV was significantly higher in
ZOL and ZOL+DEX compared to CON. p < 0.05 versus 4 week time-point within group
(#), versus CON-treatment within time point (*), or versus DEX- treatment within time point
(^).
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Figure 4.
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Histological assessment of intra-cortical bone formation rate in the alveolar region of the
mandible. Labeled osteon number (A) and bone formation rate (B) were assessed in the
alveolar bone adjacent to the extraction site by measuring fluorochrome labels injected at the
end of the experiment. Both parameters were significantly lower at both 4 and 8 weeks posthealing in ZOL and ZOL+DEX groups compared to both CON and DEX groups. p < 0.05
versus CON-treatment within time point (*) or versus DEX- treatment within time point (^).

NIH-PA Author Manuscript
NIH-PA Author Manuscript
J Oral Maxillofac Surg. Author manuscript; available in PMC 2014 June 01.

Allen et al.

Page 18

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
J Oral Maxillofac Surg. Author manuscript; available in PMC 2014 June 01.

Allen et al.

Page 19

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 5.

MicroCT images from human ONJ specimens that suggest a similar type of periosteal
reaction as noted in the present study. Specimens were scanned and analyzed for a separate
study [18].
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Table 1

Descriptive information from extraction sites
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Control

Dexamethasone

Zoledronate

Zoledronate +
Dexamethasone

Root fractures

2 of 24

0 of 24

4 of 24

4 of 24

Periosteal reaction 4 wk

0 of 6

0 of 6

3 of 6

5 of 6

Periosteal reaction 8 wk

0 of 6

0 of 6

4 of 6

3 of 6
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Table 2

Dynamic histomorphometry data of intra-cortical rib and tibial bone
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CON

DEX

ZOL

ZOL+DEX

Labeled osteon number, #/mm2

2.88 ± 0.51

1.26 ± 0.41

0.07 ± 0.02

0.05 ± 0.02

Bone formation rate, %/year

23.7 ± 4.6

14.6 ± 3.6

NA

NA

0.40 ± 0.10

0.07 ± 0.02

0.05 ± 0.01

0.03 ± 0.01

3.7 ± 1.3

0.3 ± 0.2

0.2 ± 0.1

NA

Rib

Tibia
Labeled osteon number, #/mm2
Bone formation rate, %/year
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